Shlyakhov EN, Rubinstein E. 1994a. Human live anthrax vaccine in the former USSR. Vaccine 12(8):727–730.

Shlyakhov E, Rubinstein E. 1994b. Delayed hypersensitivity after anthrax vaccination. I. Study in guinea pigs vaccinated against anthrax. Medecine Tropicale 54(1):33–37.

Simpson LL. 1989. Botulinum Neurotoxin and Tetanus Toxin. San Diego, CA: Academic Press.

Simpson LL. 1993. Botulinum toxin. In: Corn M, ed. Handbook of Hazardous Materials. New York: Academic Press. Pp. 91–98.

Singh Y, Ivins BE, Leppla SH. 1998. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect Immun 66(7): 3447–3448.

Smith LA. 1998. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 36(11):1539–1548.

Stefanova EP. 1968. On the Nature of Immunity in Anthrax. The Effect of Trauma and the Significance of Nervous System in the Immunity in Anthrax. Communication III. Available from the National Technical Information Service. AD-833 624/0/XAB.

Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA. 1996. Development of novel vaccines against anthrax in man. J Biotechnol 44(1–3):155–160.

Sterne M. 1939. The use of anthrax vaccine prepared from avirulent (uncapsulated) variants of Bacillus anthracis. Onderstepoort Journal of Veterinary Science and Animal Industry 13(2):307–312.

Sterne M, Nicol J, Lambrechts MC. 1942. The effect of large scale active immunization against anthrax. J S African Vet Med Assoc 13:53–63.

Strandberg TE, Tilvis RS, Miettinen TA. 1990. Metabolic variables of cholesterol during squalene feeding in humans: Comparison with cholestyramine treatment. J Lipid Res 31(9):1637–1643.

Sverdrup B, Klareskog L, Kleinau S. 1998. Common commercial cosmetic products induce arthritis in the DA rat. Environ Health Perspect 106(1):27–32.


Takafuji ET, Russell PK. 1990. Military immunizations: Past, present, and future prospects. Infect Dis Clin North Am 4(1):143–158.

Tammemagi L, Grant KM. 1967. Vaccination in the control of bovine botulism in Queensland. Aust Vet J 43(9):368–372.

Tanner WB, Potter ME, Teclaw RF, et al. 1978. Public health aspects of anthrax vaccination of dairy cattle. J Am Vet Med Assoc 173(11):1465–1466.

Thomas RJ, Rosenthal DV, Rogers RJ. 1988. A Clostridium botulinum type B vaccine for prevention of shaker foal syndrome. Aust Vet J 65(3):78–80.

Tsui JK. 1996. Botulinum toxin as a therapeutic agent. Pharmacol Ther 72(1):13–24.

Turnbull PC, ed. 1990. Proceedings of the International Workshop on Anthrax, Winchester, England, April 11–13, 1989. Salisbury Medical Bulletin 68:(Special Supplement).

Turnbull PC. 1991. Anthrax vaccines: Past, present and future. Vaccine 9(8):533–539.

Turnbull PC, Broster MG, Carman JA, Manchee RJ, Melling J. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 52(2):356–363.

Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J. 1988. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol (Berl) 177(5):293–303.


U.K. Ministry of Defence. 2000. Implementation of the Immunisation Programme Against Biological Warfare Agents for UK Forces During the Gulf Conflict 1990/1991. [On-



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement